• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

尼克罗米胺在 SARS-CoV-2 感染的人类气道模型中显示出强大的抗病毒活性，并对 Alpha（B.1.1.7）、Beta（B.1.351）和 Delta 变异株（B.1.617.2）保持有效。

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).

机构信息

UNION therapeutics Research Services, Hellerup, Denmark.

Novo Nordisk Center for Biosustainability, Technical University Denmark, Lyngby, Denmark.

出版信息

PLoS One. 2021 Dec 2;16(12):e0260958. doi: 10.1371/journal.pone.0260958. eCollection 2021.

DOI:10.1371/journal.pone.0260958
PMID:34855904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8639074/
Abstract

SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.

摘要

SARS-CoV-2 变种不断出现，其传播能力可能增强，突显了对新型疗法的巨大未满足医学需求。氯硝柳胺是一种有效的抗 SARS-CoV-2 药物，已进入临床开发阶段。我们在 SARS-CoV-2 人类气道模型中验证了氯硝柳胺的强大抗病毒功效。此外，氯硝柳胺对 D614G、Alpha（B.1.1.7）、Beta（B.1.351）和 Delta（B.1.617.2）变体仍然保持其效力。我们的数据进一步支持氯硝柳胺对 SARS-CoV-2 的强大抗病毒特性，并强调其作为 COVID-19 治疗药物的巨大潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae47/8639074/f3c5cbe5c387/pone.0260958.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae47/8639074/7262f2d9b4a0/pone.0260958.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae47/8639074/f3c5cbe5c387/pone.0260958.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae47/8639074/7262f2d9b4a0/pone.0260958.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae47/8639074/f3c5cbe5c387/pone.0260958.g002.jpg

相似文献

1
Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2).尼克罗米胺在 SARS-CoV-2 感染的人类气道模型中显示出强大的抗病毒活性，并对 Alpha（B.1.1.7）、Beta（B.1.351）和 Delta 变异株（B.1.617.2）保持有效。
PLoS One. 2021 Dec 2;16(12):e0260958. doi: 10.1371/journal.pone.0260958. eCollection 2021.
2
Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.尼克罗米司对安慰剂在 SARS-CoV-2 呼吸道病毒清除、病毒脱落和 COVID-19 轻症至中度患者症状持续时间方面的疗效：一项 2 期随机临床试验。
JAMA Netw Open. 2022 Feb 1;5(2):e2144942. doi: 10.1001/jamanetworkopen.2021.44942.
3
Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms.姜黄素通过多种抗病毒机制抑制 Vero E6 细胞中的体外 SARS-CoV-2 感染。
Molecules. 2021 Nov 16;26(22):6900. doi: 10.3390/molecules26226900.
4
TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).TMPRSS2 和 RNA 依赖性 RNA 聚合酶是治疗由 SARS-CoV-2 变异株（B.1.1.7 和 B.1.351）引起的 COVID-19 的有效治疗靶点。
Microbiol Spectr. 2021 Sep 3;9(1):e0047221. doi: 10.1128/Spectrum.00472-21. Epub 2021 Aug 11.
5
Niclosamide for Covid-19: bridging the gap.尼氯硝唑治疗 COVID-19：弥合差距。
Mol Biol Rep. 2021 Dec;48(12):8195-8202. doi: 10.1007/s11033-021-06770-7. Epub 2021 Oct 18.
6
Niclosamide-A promising treatment for COVID-19.氯硝柳胺——一种有前景的新冠病毒治疗药物。
Br J Pharmacol. 2022 Jul;179(13):3250-3267. doi: 10.1111/bph.15843. Epub 2022 Apr 11.
7
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.广谱抗病毒药物氯硝柳胺及其治疗潜力。
ACS Infect Dis. 2020 May 8;6(5):909-915. doi: 10.1021/acsinfecdis.0c00052. Epub 2020 Mar 10.
8
The Next Generation COVID-19 Antiviral; Niclosamide-Based Inorganic Nanohybrid System Kills SARS-CoV-2.下一代新冠病毒抗病毒药物；基于氯硝柳胺的无机纳米杂化系统可杀死新冠病毒。
Small. 2024 Sep;20(39):e2305148. doi: 10.1002/smll.202305148. Epub 2023 Aug 27.
9
The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.罗卡胍 CR-31-B（-）在体外和离体条件下以非细胞毒性、低纳摩尔浓度抑制 SARS-CoV-2 复制。
Antiviral Res. 2021 Feb;186:105012. doi: 10.1016/j.antiviral.2021.105012. Epub 2021 Jan 8.
10
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.口服蛋白酶抑制剂（PF-07321332）可保护叙利亚仓鼠免受高关注变异 SARS-CoV-2 病毒株的感染。
Nat Commun. 2022 Feb 15;13(1):719. doi: 10.1038/s41467-022-28354-0.

引用本文的文献

1
Kyasanur Forest Disease Virus: Epidemiological Insights, Pathogenesis, Therapeutic Strategies, and Advances in Vaccines and Diagnostics.基孔肯雅森林病病毒：流行病学见解、发病机制、治疗策略以及疫苗与诊断技术的进展
Viruses. 2025 Jul 22;17(8):1022. doi: 10.3390/v17081022.
2
A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19.一项关于氯硝柳胺纳米复合物治疗轻至中度新型冠状病毒肺炎患者的随机、双盲、安慰剂对照试验。
Nat Commun. 2025 Aug 1;16(1):7084. doi: 10.1038/s41467-025-62423-4.
3
Transforming Niclosamide through Nanotechnology: A Promising Approach for Long COVID Management.

本文引用的文献

1
TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).TMPRSS2 和 RNA 依赖性 RNA 聚合酶是治疗由 SARS-CoV-2 变异株（B.1.1.7 和 B.1.351）引起的 COVID-19 的有效治疗靶点。
Microbiol Spectr. 2021 Sep 3;9(1):e0047221. doi: 10.1128/Spectrum.00472-21. Epub 2021 Aug 11.
2
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.Imatinib 的临床前评估不支持其作为抗 SARS-CoV-2 的抗病毒药物使用。
Antiviral Res. 2021 Sep;193:105137. doi: 10.1016/j.antiviral.2021.105137. Epub 2021 Jul 12.
3
通过纳米技术改造氯硝柳胺：一种治疗新冠后遗症的有前景的方法。
Small. 2025 Jul;21(27):e2410345. doi: 10.1002/smll.202410345. Epub 2025 May 19.
4
Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V platform trial.COVID-19感染风险的肾病患者预防措施：PROTECT-V平台试验中鼻内使用氯硝柳胺随机、双盲、安慰剂对照组的结果。
BMC Infect Dis. 2025 Feb 11;25(1):204. doi: 10.1186/s12879-025-10584-4.
5
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial.使用氟伏沙明、溴己新、赛庚啶和氯硝柳胺进行早期治疗以预防有症状的COVID-19患者临床病情恶化：一项随机临床试验。
EClinicalMedicine. 2024 Mar 14;70:102517. doi: 10.1016/j.eclinm.2024.102517. eCollection 2024 Apr.
6
Clinical development of antivirals against SARS-CoV-2 and its variants.抗SARS-CoV-2及其变体抗病毒药物的临床开发。
Curr Res Microb Sci. 2023 Dec 2;6:100208. doi: 10.1016/j.crmicr.2023.100208. eCollection 2024.
7
Repurposing Niclosamide as a Novel Anti-SARS-CoV-2 Drug by Restricting Entry Protein CD147.通过靶向进入蛋白CD147将氯硝柳胺重新用作新型抗SARS-CoV-2药物
Biomedicines. 2023 Jul 18;11(7):2019. doi: 10.3390/biomedicines11072019.
8
Use of physiological based pharmacokinetic modeling for cross-species prediction of pharmacokinetic and tissue distribution profiles of a novel niclosamide prodrug.基于生理学的药代动力学建模在新型氯硝柳胺前药药代动力学和组织分布特征跨物种预测中的应用
Front Pharmacol. 2023 Apr 11;14:1099425. doi: 10.3389/fphar.2023.1099425. eCollection 2023.
9
Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147.通过抑制进入蛋白CD147将氯硝柳胺重新用作新型抗SARS-CoV-2药物。
Res Sq. 2023 Apr 13:rs.3.rs-2763207. doi: 10.21203/rs.3.rs-2763207/v1.
10
Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections.从市售的已获批准片剂中提取氯硝柳胺，并将其制成水性缓冲溶液，可制备出可能获得批准的用于对抗COVID-19和其他呼吸道感染的口服和鼻喷雾剂。
AAPS Open. 2023;9(1):9. doi: 10.1186/s41120-023-00072-x. Epub 2023 Apr 14.
SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals.
SARS-CoV-2 介导的代谢和自噬失调揭示了针对宿主的抗病毒药物。
Nat Commun. 2021 Jun 21;12(1):3818. doi: 10.1038/s41467-021-24007-w.
4
Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.截至2021年6月，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株的传播性增加及其在全球的传播情况。
Euro Surveill. 2021 Jun;26(24). doi: 10.2807/1560-7917.ES.2021.26.24.2100509.
5
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.吸入和鼻内使用氯硝柳胺的随机、双盲、安慰剂对照1期试验：一种用于治疗COVID-19的广谱抗病毒候选药物。
Lancet Reg Health Eur. 2021 May;4:100084. doi: 10.1016/j.lanepe.2021.100084. Epub 2021 Apr 6.
6
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.抑制 TMEM16 蛋白的药物可阻断 SARS-CoV-2 刺突诱导的合胞体。
Nature. 2021 Jun;594(7861):88-93. doi: 10.1038/s41586-021-03491-6. Epub 2021 Apr 7.
7
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
8
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株B.1.351和B.1.1.7对抗体中和作用的抗性增强。
Res Sq. 2021 Jan 29:rs.3.rs-155394. doi: 10.21203/rs.3.rs-155394/v1.
9
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant.新冠病毒：诺瓦瓦克斯疫苗对英国变种的效力为86%，对南非变种的效力为60%。
BMJ. 2021 Feb 1;372:n296. doi: 10.1136/bmj.n296.
10
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.BNT162b2疫苗诱导产生的血清对N501Y突变型严重急性呼吸综合征冠状病毒2的中和作用。
bioRxiv. 2021 Jan 7:2021.01.07.425740. doi: 10.1101/2021.01.07.425740.